FI59585C - Foerfarande foer framstaellning av pao hjaerta och blodcirkulation verkande n-substituerade 1-amino-3-fenoxi-propanoler-(2) - Google Patents
Foerfarande foer framstaellning av pao hjaerta och blodcirkulation verkande n-substituerade 1-amino-3-fenoxi-propanoler-(2) Download PDFInfo
- Publication number
- FI59585C FI59585C FI2296/74A FI229674A FI59585C FI 59585 C FI59585 C FI 59585C FI 2296/74 A FI2296/74 A FI 2296/74A FI 229674 A FI229674 A FI 229674A FI 59585 C FI59585 C FI 59585C
- Authority
- FI
- Finland
- Prior art keywords
- compounds
- phenoxy
- formula
- preparation
- group
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 8
- 230000017531 blood circulation Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 30
- FQYUMYWMJTYZTK-UHFFFAOYSA-N Phenyl glycidyl ether Chemical compound C1OC1COC1=CC=CC=C1 FQYUMYWMJTYZTK-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 2
- 101150065749 Churc1 gene Proteins 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 102100038239 Protein Churchill Human genes 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- DSNYFFJTZPIKFZ-UHFFFAOYSA-N propoxybenzene Chemical compound CCCOC1=CC=CC=C1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 239000013078 crystal Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 239000001530 fumaric acid Substances 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- GEPMAHVDJHFBJI-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C GEPMAHVDJHFBJI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- -1 N-substituted 1-amino-3-phenoxypropan-2-ols Chemical class 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AXWYRJZSJKENFE-UHFFFAOYSA-N 1-carbazol-9-ylpropan-2-amine Chemical compound C1=CC=C2N(CC(N)C)C3=CC=CC=C3C2=C1 AXWYRJZSJKENFE-UHFFFAOYSA-N 0.000 description 2
- YFYYZBZNFQDFKX-UHFFFAOYSA-N 2-carbazol-9-yl-n-methylethanamine Chemical compound C1=CC=C2N(CCNC)C3=CC=CC=C3C2=C1 YFYYZBZNFQDFKX-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 150000003944 halohydrins Chemical class 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- SWCDLFGVNXNURM-UHFFFAOYSA-N 1-amino-3-phenoxypropan-1-ol Chemical compound NC(O)CCOC1=CC=CC=C1 SWCDLFGVNXNURM-UHFFFAOYSA-N 0.000 description 1
- JZEHWMUIAKALDN-UHFFFAOYSA-N 1-amino-3-phenoxypropan-2-ol Chemical compound NCC(O)COC1=CC=CC=C1 JZEHWMUIAKALDN-UHFFFAOYSA-N 0.000 description 1
- KVXVLRNRISJFAG-UHFFFAOYSA-N 1-carbazol-9-ylpropan-2-yl methanesulfonate Chemical compound C1=CC=C2N(CC(C)OS(C)(=O)=O)C3=CC=CC=C3C2=C1 KVXVLRNRISJFAG-UHFFFAOYSA-N 0.000 description 1
- HJDPZRKNMOFAFY-UHFFFAOYSA-N 1-phenothiazin-10-ylpropan-2-amine Chemical compound C1=CC=C2N(CC(N)C)C3=CC=CC=C3SC2=C1 HJDPZRKNMOFAFY-UHFFFAOYSA-N 0.000 description 1
- UYZINJBKKBQQLE-UHFFFAOYSA-N 1-phenoxy-3-[2-(n-phenylanilino)ethylamino]propan-2-ol Chemical compound C=1C=CC=CC=1OCC(O)CNCCN(C=1C=CC=CC=1)C1=CC=CC=C1 UYZINJBKKBQQLE-UHFFFAOYSA-N 0.000 description 1
- BXMXGIZWHZIJPA-UHFFFAOYSA-N 11-(3-chloropropyl)-5,6-dihydrobenzo[b][1]benzazepine Chemical compound C1CC2=CC=CC=C2N(CCCCl)C2=CC=CC=C21 BXMXGIZWHZIJPA-UHFFFAOYSA-N 0.000 description 1
- ISJPYOAVAUNLDZ-UHFFFAOYSA-N 11-(oxiran-2-ylmethyl)-5,6-dihydrobenzo[b][1]benzazepine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CC1CO1 ISJPYOAVAUNLDZ-UHFFFAOYSA-N 0.000 description 1
- OYGMIRMOXJHJFF-UHFFFAOYSA-N 2-carbazol-9-ylethanamine Chemical compound C1=CC=C2N(CCN)C3=CC=CC=C3C2=C1 OYGMIRMOXJHJFF-UHFFFAOYSA-N 0.000 description 1
- MGAVUWZVRONRRE-UHFFFAOYSA-N 2-carbazol-9-ylethyl methanesulfonate Chemical compound C1=CC=C2N(CCOS(=O)(=O)C)C3=CC=CC=C3C2=C1 MGAVUWZVRONRRE-UHFFFAOYSA-N 0.000 description 1
- GEQNUMNORCDKBC-UHFFFAOYSA-N 2-phenothiazin-10-ylethanamine Chemical compound C1=CC=C2N(CCN)C3=CC=CC=C3SC2=C1 GEQNUMNORCDKBC-UHFFFAOYSA-N 0.000 description 1
- BVWVHDAZJIEDID-UHFFFAOYSA-N 3-carbazol-9-ylpropan-1-amine Chemical compound C1=CC=C2N(CCCN)C3=CC=CC=C3C2=C1 BVWVHDAZJIEDID-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- OZECFIJVSAYAPH-UHFFFAOYSA-N ethyl-di(propan-2-yl)azanium;chloride Chemical compound Cl.CCN(C(C)C)C(C)C OZECFIJVSAYAPH-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- PADPKJACPLYMPK-UHFFFAOYSA-N n',n'-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1N(CCN)C1=CC=CC=C1 PADPKJACPLYMPK-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000008019 pharmaceutical lubricant Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2339396A DE2339396C2 (de) | 1973-08-03 | 1973-08-03 | N-substituierte 1-Amino-3-phenoxypropan-2-ole, deren Salze, Verfahren zu deren Herstellung sowie Arzneimittel, die diese Verbindungen enthalten |
| DE2339396 | 1973-08-03 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI229674A7 FI229674A7 (de) | 1975-02-04 |
| FI59585B FI59585B (fi) | 1981-05-29 |
| FI59585C true FI59585C (fi) | 1981-09-10 |
Family
ID=5888826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI2296/74A FI59585C (fi) | 1973-08-03 | 1974-07-31 | Foerfarande foer framstaellning av pao hjaerta och blodcirkulation verkande n-substituerade 1-amino-3-fenoxi-propanoler-(2) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US3998810A (de) |
| JP (1) | JPS5843388B2 (de) |
| AR (2) | AR202941A1 (de) |
| AT (1) | AT338274B (de) |
| CA (1) | CA1037039A (de) |
| CH (1) | CH605640A5 (de) |
| DE (1) | DE2339396C2 (de) |
| ES (1) | ES428818A1 (de) |
| FI (1) | FI59585C (de) |
| FR (1) | FR2239994B1 (de) |
| GB (1) | GB1408261A (de) |
| NL (1) | NL176261C (de) |
| SE (1) | SE421693B (de) |
| ZA (1) | ZA744923B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2815926A1 (de) * | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DD146749A3 (de) * | 1977-12-01 | 1981-03-04 | Dieter Lehmann | Verfahren zur herstellung von phenoxyalkanolamin-derivaten |
| DK460879A (da) * | 1978-11-01 | 1980-05-02 | Wellcome Found | Fremgangsmaade til fremstilling af 9-(3-(3,5-cisdimethylpiperazino)propyl)carbazol et salt heraf eller et solvat af et saadant salt |
| US4772697A (en) * | 1983-08-01 | 1988-09-20 | Syntex (U.S.A.) Inc. | Tricylic antidepressant conjugates to antigens and enzymes |
| US4629691A (en) * | 1983-08-01 | 1986-12-16 | Syntex (U.S.A.) Inc. | Tricyclic antidepressant conjugates with antigens and enzymes |
| JP2004524270A (ja) | 2000-09-26 | 2004-08-12 | ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド | 長時間作用する麻酔薬および鎮痛薬としての、三環式抗うつ薬およびのそれらのアナログ |
| US7074961B2 (en) | 2000-09-26 | 2006-07-11 | The Brigham And Women's Hospital, Inc. | Antidepressants and their analogues as long-acting local anesthetics and analgesics |
| US8109968B2 (en) * | 2003-05-07 | 2012-02-07 | Anpa Medical, Inc. | Suture lock |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3068222A (en) * | 1962-12-11 | Trifluoromethyl substituted dibenzxze- | ||
| NL130988C (de) * | 1966-07-21 | Boehringer Mannheim Gmbh |
-
1973
- 1973-08-03 DE DE2339396A patent/DE2339396C2/de not_active Expired
-
1974
- 1974-07-10 US US05/487,423 patent/US3998810A/en not_active Expired - Lifetime
- 1974-07-24 CA CA205,557A patent/CA1037039A/en not_active Expired
- 1974-07-28 AR AR254937A patent/AR202941A1/es active
- 1974-07-29 GB GB3340174A patent/GB1408261A/en not_active Expired
- 1974-07-30 NL NLAANVRAGE7410220,A patent/NL176261C/xx not_active IP Right Cessation
- 1974-07-30 CH CH1049574A patent/CH605640A5/xx not_active IP Right Cessation
- 1974-07-30 JP JP49087432A patent/JPS5843388B2/ja not_active Expired
- 1974-07-31 FI FI2296/74A patent/FI59585C/fi active
- 1974-07-31 ES ES428818A patent/ES428818A1/es not_active Expired
- 1974-08-01 ZA ZA00744923A patent/ZA744923B/xx unknown
- 1974-08-01 FR FR7426716A patent/FR2239994B1/fr not_active Expired
- 1974-08-01 AT AT631374A patent/AT338274B/de not_active IP Right Cessation
- 1974-08-02 SE SE7409989A patent/SE421693B/xx unknown
- 1974-12-23 AR AR257044A patent/AR202960A1/es active
Also Published As
| Publication number | Publication date |
|---|---|
| AR202941A1 (es) | 1975-07-31 |
| NL176261C (nl) | 1985-03-18 |
| FR2239994B1 (de) | 1978-07-21 |
| NL7410220A (nl) | 1975-02-05 |
| AR202960A1 (es) | 1975-07-31 |
| JPS5843388B2 (ja) | 1983-09-27 |
| AU7180874A (en) | 1976-02-05 |
| FR2239994A1 (de) | 1975-03-07 |
| ZA744923B (en) | 1975-09-24 |
| CH605640A5 (de) | 1978-10-13 |
| ATA631374A (de) | 1976-12-15 |
| AT338274B (de) | 1977-08-10 |
| CA1037039A (en) | 1978-08-22 |
| SE421693B (sv) | 1982-01-25 |
| FI59585B (fi) | 1981-05-29 |
| SE7409989L (de) | 1975-02-04 |
| JPS5041829A (de) | 1975-04-16 |
| NL176261B (nl) | 1984-10-16 |
| DE2339396A1 (de) | 1975-02-20 |
| US3998810A (en) | 1976-12-21 |
| USB487423I5 (de) | 1976-03-02 |
| DE2339396C2 (de) | 1984-06-28 |
| GB1408261A (en) | 1975-10-01 |
| FI229674A7 (de) | 1975-02-04 |
| ES428818A1 (es) | 1976-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4460590A (en) | Diglycidyl substituted heterocyclic compounds | |
| EP0039051A2 (de) | Hydroxamsäurederivate vom Typ der Mannich-Basen mit verbesserter biologischer Verfügbarkeit von nicht-steroiden Entzündungshemmern, Verfahren zur Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzung | |
| US3574218A (en) | 2-aryl- or aralkyl-substituted benzazole derivatives | |
| FI59585C (fi) | Foerfarande foer framstaellning av pao hjaerta och blodcirkulation verkande n-substituerade 1-amino-3-fenoxi-propanoler-(2) | |
| FI67543C (fi) | Foerfarande foer framstaellning av farmakologiskt aktiv 2-(2-(1,4-benzodioxanyl))-2-imidazolin | |
| FI59588C (fi) | Foerfarande foer framstaellning av hjaertverksamheten och blodcirkulationen paoverkande tricykliskt substituerade aminopropanoler och deras icke toxiska salter | |
| SE468560B (sv) | 1-(hydroxistyryl)-5h-2,3-bensodiazepinderivat, foerfarande foer deras framstaellning samt farmaceutiska kompositioner innehaallande desamma | |
| US3247221A (en) | Benzodioxane derivatives | |
| PT92391B (pt) | Processo para a sintese de nitro-imidazois e de composicoes farmaceuticas que os contem | |
| US3931212A (en) | Method for treating cardiovascular circulatory insufficiencies and hypotonia with 2-hydroxy-phenyl-1-oxa-4-azaspiroalkane derivatives | |
| US3632587A (en) | Piperazino methyl isatinylidine 3 acetates | |
| US4144340A (en) | Basic substituted xanthine derivatives | |
| FI80269C (fi) | Foerfarande foer framstaellning av farmakologiskt vaerdefulla bis(piperazinyl- eller homopiperazinyl)alkaner. | |
| FI62089C (fi) | Foerfarande foer framstaellning av pao det perifera blodomloppet verkande 7-(n-(3-fenoxi-2-hydroxipropyl)-n-amino)-1,3-dialkyl-xantinderivat | |
| US4029783A (en) | N-substituted 1-amino-3-phenoxy-propan-2-ol compounds and therapeutic compositions containing them | |
| HU199817B (en) | Process for production of new derivatives of alkylendiamin and medical compositions containing them | |
| US4001271A (en) | 3-(isopropyl amino alkoxy)-2-phenyl-isoindolin-1-ones | |
| US4857536A (en) | Antihistaminic benzimidazole derivatives | |
| FI74704C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara anilinderivat. | |
| US3951963A (en) | 0-(Substituted-aminoalkyl)-5-nitroimidazole-(2)-aldoximes | |
| FI65427C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara xanten- eller furankarbonyloxipropanpiperazin-derivat | |
| US3821241A (en) | 1-imidazolyl-2-substituted hydroxy propyl amines | |
| US3629443A (en) | Therapeutic composition containing a mandelamidine derivative | |
| US3989833A (en) | Pharmaceutical compositions containing adenine derivatives | |
| US3951970A (en) | Resorcinol amine derivatives |